Transforming growth factor, beta 3

TGFB3
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesTGFB3, ARVD, ARVD1, RNHF, TGF-beta3, Transforming growth factor, beta 3, LDS5, transforming growth factor beta 3
External IDsMGI: 98727 HomoloGene: 2433 GeneCards: TGFB3
Gene location (Human)
Chr.Chromosome 14 (human)[1]
BandNo data availableStart75,958,099 bp[1]
End75,982,991 bp[1]
RNA expression pattern
More reference expression data
Orthologs
SpeciesHumanMouse
Entrez

7043

21809

Ensembl

ENSG00000119699

ENSMUSG00000021253

UniProt

P10600

P17125

RefSeq (mRNA)

NM_003239
NM_001329938
NM_001329939

NM_009368

RefSeq (protein)

NP_001316867
NP_001316868
NP_003230

n/a

Location (UCSC)Chr 14: 75.96 – 75.98 MbChr 14: 86.06 – 86.08 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Transforming growth factor beta-3 is a protein that in humans is encoded by the TGFB3 gene.[5][6]

It is a type of protein, known as a cytokine, which is involved in cell differentiation, embryogenesis and development. It belongs to a large family of cytokines called the Transforming growth factor beta superfamily, which includes the TGF-β family, Bone morphogenetic proteins (BMPs), growth and differentiation factors (GDFs), inhibins and activins.[7]

TGF-β3 is believed to regulate molecules involved in cellular adhesion and extracellular matrix (ECM) formation during the process of palate development. Without TGF-β3, mammals develop a deformity known as a cleft palate.[8][9] This is caused by failure of epithelial cells in both sides of the developing palate to fuse. TGF-β3 also plays an essential role in controlling the development of lungs in mammals, by also regulating cell adhesion and ECM formation in this tissue,[10] and controls wound healing by regulating the movements of epidermal and dermal cells in injured skin.[5]

Interactions

Transforming growth factor, beta 3 has been shown to interact with TGF beta receptor 2.[11][12][13][14]

Clinical research

After successful phase I/II trials,[15] human recombinant TGF-β3 (Avotermin, planned trade name Juvista) failed in Phase III trials.[16]

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000119699 - Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000021253 - Ensembl, May 2017
  3. ↑ "Human PubMed Reference:".
  4. ↑ "Mouse PubMed Reference:".
  5. 1 2 Bandyopadhyay B, Fan J, Guan S, Li Y, Chen M, Woodley DT, Li W (Mar 2006). "A "traffic control" role for TGFbeta3: orchestrating dermal and epidermal cell motility during wound healing". The Journal of Cell Biology. 172 (7): 1093–105. PMC 2063766 Freely accessible. PMID 16549496. doi:10.1083/jcb.200507111.
  6. ↑ "Entrez Gene: TGFB3 transforming growth factor, beta 3".
  7. ↑ Herpin A, Lelong C, Favrel P (May 2004). "Transforming growth factor-beta-related proteins: an ancestral and widespread superfamily of cytokines in metazoans". Developmental and Comparative Immunology. 28 (5): 461–85. PMID 15062644. doi:10.1016/j.dci.2003.09.007.
  8. ↑ Taya Y, O'Kane S, Ferguson MW (Sep 1999). "Pathogenesis of cleft palate in TGF-beta3 knockout mice". Development. 126 (17): 3869–79. PMID 10433915.
  9. ↑ Dudas M, Nagy A, Laping NJ, Moustakas A, Kaartinen V (Feb 2004). "Tgf-beta3-induced palatal fusion is mediated by Alk-5/Smad pathway". Developmental Biology. 266 (1): 96–108. PMID 14729481. doi:10.1016/j.ydbio.2003.10.007.
  10. ↑ Kaartinen V, Voncken JW, Shuler C, Warburton D, Bu D, Heisterkamp N, Groffen J (Dec 1995). "Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction". Nature Genetics. 11 (4): 415–21. PMID 7493022. doi:10.1038/ng1295-415.
  11. ↑ De Crescenzo G, Pham PL, Durocher Y, O'Connor-McCourt MD (May 2003). "Transforming growth factor-beta (TGF-beta) binding to the extracellular domain of the type II TGF-beta receptor: receptor capture on a biosensor surface using a new coiled-coil capture system demonstrates that avidity contributes significantly to high affinity binding". Journal of Molecular Biology. 328 (5): 1173–83. PMID 12729750. doi:10.1016/S0022-2836(03)00360-7.
  12. ↑ Hart PJ, Deep S, Taylor AB, Shu Z, Hinck CS, Hinck AP (Mar 2002). "Crystal structure of the human TbetaR2 ectodomain--TGF-beta3 complex". Nature Structural Biology. 9 (3): 203–8. PMID 11850637. doi:10.1038/nsb766.
  13. ↑ Barbara NP, Wrana JL, Letarte M (Jan 1999). "Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily". The Journal of Biological Chemistry. 274 (2): 584–94. PMID 9872992. doi:10.1074/jbc.274.2.584.
  14. ↑ Rotzer D, Roth M, Lutz M, Lindemann D, Sebald W, Knaus P (Feb 2001). "Type III TGF-beta receptor-independent signalling of TGF-beta2 via TbetaRII-B, an alternatively spliced TGF-beta type II receptor". The EMBO Journal. 20 (3): 480–90. PMC 133482 Freely accessible. PMID 11157754. doi:10.1093/emboj/20.3.480.
  15. ↑ Ferguson MW, Duncan J, Bond J, Bush J, Durani P, So K, Taylor L, Chantrey J, Mason T, James G, Laverty H, Occleston NL, Sattar A, Ludlow A, O'Kane S (Apr 2009). "Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies". Lancet. 373 (9671): 1264–74. PMID 19362676. doi:10.1016/S0140-6736(09)60322-6.
  16. ↑ Renovo shares plummet 75% as scar revision product Juvista fails to meet study endpoints, 14 February 2011

Further reading

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.